HBOT, IV Vitamin Drops to Boost Patient Immunity amid COVID-19 Pandemic
Healthcare facilities such as the Hyperbaric Medical Solutions is taking extra preventive steps to mitigate the risks of the coronavirus pandemic to ensure all patients are offered clean and safe environments. Stakeholders in the radiation proctitis market are increasing efforts to boost the availability for hyperbaric oxygen therapy (HBOT), which is being associated with enhancing the immune system in the wake of the COVID-19 outbreak.
Get the sample copy of report@ https://qyresearchmedical.com/sample/111548
Companies in the radiation proctitis market are maintaining steady supply of intravenous (IV) vitamin drips, which help to strengthen the immunity of patients and help in detoxification. However, a slowdown in the global economy may have affected revenue collections in healthcare facilities. Hence, healthcare companies should adopt flexible business strategies, and team up with their stakeholders in the value chain to manage investments and product launches.
Alternative Trials Design Help Overcome Uncertainties in Controlled Trials for HBOT
HBOT is emerging as the gold standard for treating radiation toxicity. However, this treatment is being associated with side effects such as transient myopia, fatigue, and barotrauma. Moreover, patients with severe complaints refrain from participating and even opt out of randomized controlled trials. Hence, companies in the radiation proctitis market are collaborating with research institutes to create alternative trials design in order to overcome the issues in trials within cohorts design.
The approval of the U.S.-based FDA (Food & Drug Association) for HBOT is creating incremental opportunities for companies in the radiation proctitis market. This explains why the market is expected to reach US$ 748.5 Mn by 2030.
Topical Corticosteroids, Antidiarrheal Therapies Improve Medical Outcomes
Improvements in radiotherapy techniques are enabling superior delivery of radiation doses, and have the potential to easily reduce cases of both chronic and acute proctitis. Despite these advancements, the radiation proctitis market is projected to register a favorable CAGR of ~7% during the assessment period, owing to a high prevalence of radiation toxicity.
View full report@ https://qyresearchmedical.com/report/radiation-proctitis-market-indication-acute-radiation-proctitis-and-chronic-radiation-proctitis-and-therapy-oral-therapy-ablative-procedures-hyperbaric-oxygen-therapyformalin-and-surgery-global-industry-a-2020-2030/111548
Healthcare providers in the radiation proctitis market are gaining proficiency iron substitution therapies. Manufacturers are boosting their output capacities in topical corticosteroids, sucralfate injections, and increasing R&D in antidiarrheal therapies, since the latter is gaining popularity as an aggressive means for patient care.
Intraperitoneal Injections, Colostomy Translate into Growth Opportunities for Healthcare Providers
Apart from oral therapies, companies and healthcare providers in the radiation proctitis market are offering remedial laser techniques in cases of continuous rectal bleeding. Clinicians are attempting formaldehyde administration before the surgical therapy. Healthcare professionals are conducting a descending or transverse colostomy for patients when surgery is required. Companies in the radiation proctitis market are increasing the availability of intraperitoneal injections of formalin.
Novel methods of cold therapy and radiofrequency ablation (RFA) are grabbing the attention of healthcare providers. Colostomy is gaining prominence as an effective and safe procedure for treating rectal ulcer of chronic radiation proctitis patients. Colostomy helps to control rectal bleeding and effectively relieve pain in patients.
Prostaglandins Aid in Healing of Inflammation, Wounds in Prostate Cancer Patients
The high prevalence of hemorrhagic radiation proctitis is acting as a key driver for the expansion of the radiation proctitis market. However, the lack of consensus for the management of hemorrhagic radiation proctitis is likely to inhibit market growth. Despite the challenges, clinicians are adopting rectal resection as an available option for hemorrhagic radiation proctitis management.
Healthcare companies in the radiation proctitis market are increasing their R&D in prostaglandins that aid in the healing of inflammation and wounds. This has led to the popularity of misoprostol, which is found to be efficacious in treating complications that arise in patients with prostate cancer that receive radiation therapy. Misoprostol rectal suppositories are being highly publicized for reducing the complications associated with acute and chronic radiation proctitis.
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111548/2900
Healthcare providers are providing uncompromised care services to radiation proctitis patients despite reduced hospital and clinical visits during the ongoing COVID-19 outbreak. Even as the National Comprehensive Cancer Network (NCCN) is setting guidelines for the Radiation Therapy Compendium™ Development, companies and healthcare providers are increasing efforts to gain proficiency in HBOT. However, HBOT is associated with oxygen toxicity and seizures. Hence, companies and healthcare professionals in the radiation proctitis market should encourage patients to participate in controlled trials and alternative trial design to improve medical outcomes. As such, manufacturers are increasing their focus in stool softeners and treatments that heal tissues in order to minimize patient complications.
Radiation Proctitis Market: Overview
The global radiation proctitis market for the historical period 2018–2019 and forecast period 2020–2030, surge in adoption of advanced technologies to treat cancer is projected to boost the growth of the global market
Radiation proctitis is inflammation of the rectum due to exposure of X rays or other ionizing radiation. The management of radiation proctitis is divided into invasive and non-invasive treatment. Non-invasive treatment includes anti-inflammatory agents, sucralfate, short-chain fatty acids, hyperbaric, and antioxidants.
Rise in Prevalence of Cancer to Drive Radiation Proctitis Market
Increase in incidence of prostate cancer, owing to genetic alterations & family history drives the demand for advanced therapy, which, in turn, boosts the growth of the global radiation proctitis market. Prostate cancer is the second most frequently diagnosed cancer in men and the fifth leading cause of death globally. The incidence of anal cancer has increased significantly in the last decade, and is currently estimated to be ~1.5 per 100,000 in the general population of the U.S., particularly in certain population subgroups.
Increase in Adoption of Radiation Therapy to Treat Cancer to Propel Radiation Proctitis Market
Over 14 million new cases of cancer are diagnosed globally each year. Radiation therapy (RT) has the potential to improve the rates of cure of 3.5 million people and provide palliative relief for an additional 3.5 million people.
Radiotherapy is the most commonly use treatment for cancer regimen in countries in the West. Technological advancements with a better understanding of tumor biology at the molecular, cellular, physiological, and immunological levels have improved the treatment efficacy of radiotherapy. This is anticipated to drive the adoption of radiation therapy, which is expected to boost the global radiation proctitis market.
High Cost of Hyperbaric Oxygen Therapy to Hamper Radiation Proctitis Market
Cost is one of the major factors that influences the selection of treatment. Hyperbaric oxygen therapy is one of the few treatments for patients with severe radiation-induced symptoms, which include proctitis and cystitis with bleeding. Currently, hyperbaric oxygen therapy is expensive and therefore, the economically weak cannot afford it, despite the significant therapeutic effects. This acts as a major restraint of the global radiation proctitis market.
Radiation Proctitis Market: Competition Landscape
This report profiles major players operating in the global radiation proctitis market based on various attributes and recent developments
The global radiation proctitis market is highly fragmented, with the presence of a large number of global as well as regional players
Leading players operating in the global radiation proctitis market include
- Allergan plc
- Teva Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals, Inc.
- Pfizer, Inc.
- Mylan, Inc. (Viatris)
- Johnson & Johnson (Johnson & Johnson Consumer, Inc.)
- Sun Pharmaceutical Industries Ltd.
- Environmental Tectonics Corporation
- Sechrist Industries, Inc.
Radiation Proctitis Market: Key Developments
Key players in the global radiation proctitis market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are aimed at strengthening the product portfolio and investing in research & development. A few expansion strategies adopted by players operating in the global radiation proctitis market are:
In December 2020, Pfizer, Inc. and Myovant Sciences entered into a collaboration to develop and commercialize relugolix. It is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist in women’s health and oncology in the U.S. and Canada.
In December 2019, Amneal entered into a definitive agreement under which, Amneal will acquire a 65.1% majority interest in AvKARE and its related affiliate doing business. The deal was valued at US$ 340 Mn.
In August 2019, Sun Pharmaceutical Industries Ltd. entered into a collaboration with China Medical System Holdings. This collaboration enabled the company to enter into the generic pharmaceutical market in China.
The report on the global radiation proctitis market discussed individual strategies, followed by company profiles of manufacturers of radiation proctitis products. The competition landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global radiation proctitis market.
Key Questions Answered in Radiation Proctitis Market Report
- What are the major drivers, restraints, and opportunities in the market?
- What are the revenue share projections of key segments of the global radiation proctitis market during the forecast period?
- Which segment is likely to lead the global radiation proctitis market in terms of revenue by 2030?
- How mergers & acquisitions among players are widening the scope for the global radiation proctitis market?
- What is the market position of different companies operating in the global radiation proctitis market?
Radiation Proctitis Market – Segmentation
- Acute Radiation Proctitis
- Chronic Radiation Proctitis
- Oral Therapy
- Anti-inflammatory Agents
- Ablative Procedures
- Hyperbaric Oxygen Therapy
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
TABLE OF CONTENT
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Radiation Proctitis market
4. Market Overview
4.3. Market Dynamics
4.4. Global Radiation Proctitis Market Analysis and Forecast, 2018–2030
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
5. Market Outlook
5.1. Prevalence of Urinary Incontinence, by Region
5.2. Key Industry Events
5.3. Regulatory Scenario
5.4. Technological Advancements
5.5. Key Success Factors of Top Players
6. Global Radiation Proctitis Market Value (US$ Mn) Forecast, by Indication
6.1. Introduction & Definition
6.2. Global Radiation Proctitis Market Value Forecast, by Indication, 2018–2030
6.2.1. Acute Radiation Proctitis
6.2.2. Chronic Radiation Proctitis
6.3. Global Radiation Proctitis Market Attractiveness Analysis, by Indication
7. Global Radiation Proctitis Market Value (US$ Mn) Forecast, by Therapy
7.1. Introduction & Definition
7.2. Global Radiation Proctitis Market Value Forecast, by Therapy, 2018–2030
7.2.1. Oral Therapy
22.214.171.124. Anti-inflammatory Agents
7.2.2. Ablative Procedures
7.2.3. Hyperbaric Oxygen Therapy
8. Global Radiation Proctitis Market Value (US$ Mn) Forecast, by Region
8.2. Radiation Proctitis Market Value Forecast, by Region, 2018–2030
8.2.1. North America
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Global Radiation Proctitis Market Attractiveness Analysis, by Region
9. North America Radiation Proctitis Market Analysis and Forecast
9.2. North America Radiation Proctitis Market Value Forecast, by Indication, 2018–2030
9.2.1. Acute Radiation Proctitis
9.2.2. Chronic Radiation Proctitis
9.3. North America Radiation Proctitis Market Value Forecast, by Therapy, 2018–2030
9.3.1. Oral Therapy
126.96.36.199. Anti-inflammatory Agents
9.3.2. Ablative Procedures
9.3.3. Hyperbaric Oxygen Therapy
9.4. North America Radiation Proctitis Market Value Forecast, by Country/Sub-region, 2018–2030
9.5. North America Radiation Proctitis Market Attractiveness Analysis
9.5.1. By Indication
9.5.2. By Therapy
9.5.3. By Country/Sub-region
10. Europe Radiation Proctitis Market Analysis and Forecast
10.2. Europe Radiation Proctitis Market Value Forecast, by Indication, 2018–2030
10.2.1. Acute Radiation Proctitis
10.2.2. Chronic Radiation Proctitis
10.3. Europe Radiation Proctitis Market Value Forecast, by Therapy, 2018–2030
10.3.1. Oral Therapy
10.3.1.2. Anti-inflammatory Agents
10.3.2. Ablative Procedures
10.3.3. Hyperbaric Oxygen Therapy
10.4. Europe Radiation Proctitis Market Value Forecast, by Country/Sub-region, 2018–2030
10.4.6. Rest of Europe
10.5. Europe Radiation Proctitis Market Attractiveness Analysis
10.5.1. By Indication
10.5.2. By Therapy
10.5.3. By Country/Sub-region
11. Asia Pacific Radiation Proctitis Market Analysis and Forecast
11.2. Asia Pacific Radiation Proctitis Market Value Forecast, by Indication, 2018–2030
11.2.1. Acute Radiation Proctitis
11.2.2. Chronic Radiation Proctitis
11.3. Asia Pacific Radiation Proctitis Market Value Forecast, by Therapy, 2018–2030
11.3.1. Oral Therapy
188.8.131.52. Anti-inflammatory Agents
11.3.2. Ablative Procedures
11.3.3. Hyperbaric Oxygen Therapy
11.4. Asia Pacific Radiation Proctitis Market Value Forecast, by Country/Sub-region, 2018–2030
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Radiation Proctitis Market Attractiveness Analysis
11.5.1. By Indication
11.5.2. By Therapy
11.5.3. By Country/Sub-region
12. Latin America Radiation Proctitis Market Analysis and Forecast
12.2. Latin America Radiation Proctitis Market Value Forecast, by Indication, 2018–2030
12.2.1. Acute Radiation Proctitis
12.2.2. Chronic Radiation Proctitis
12.3. Latin America Radiation Proctitis Market Value Forecast, by Therapy, 2018–2030
12.3.1. Oral Therapy
12.3.2. Ablative Procedures
12.3.3. Hyperbaric Oxygen Therapy
12.4. Latin America Radiation Proctitis Market Value Forecast, by Country/Sub-region, 2018–2030
12.4.3. Rest of Latin America
12.5. Latin America Radiation Proctitis Market Attractiveness Analysis
12.5.1. By Indication
12.5.2. By Therapy
12.5.3. By Country/Sub-region
13. Middle East & Africa Radiation Proctitis Market Analysis and Forecast
13.2. Middle East & Africa Radiation Proctitis Market Value Forecast, by Indication, 2018–2030
13.2.1. Acute Radiation Proctitis
13.2.2. Chronic Radiation Proctitis
13.3. Middle East & Africa Radiation Proctitis Market Value Forecast, by Therapy, 2018–2030
13.3.1. Oral Therapy
184.108.40.206. Anti-inflammatory Agents
13.3.2. Ablative Procedures
13.3.3. Hyperbaric Oxygen Therapy
13.4. Middle East & Africa Radiation Proctitis Market Value Forecast, by Country/Sub-region, 2018–2030
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Middle East & Africa Radiation Proctitis Market Attractiveness Analysis
13.5.1. By Indication
13.5.2. By Therapy
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Global Radiation Proctitis Market Share Analysis, by Company, 2019
14.2. Company Profiles
14.2.1. Allergan plc
220.127.116.11. Company Description
18.104.22.168. Business Overview
22.214.171.124. Financial Overview
126.96.36.199. Strategic Overview
188.8.131.52. SWOT Analysis
14.2.2. Teva Pharmaceutical Industries Ltd.
184.108.40.206. Company Description
220.127.116.11. Business Overview
18.104.22.168. Financial Overview
22.214.171.124. Strategic Overview
126.96.36.199. SWOT Analysis
14.2.3. Amneal Pharmaceuticals, Inc.
188.8.131.52. Company Description
184.108.40.206. Business Overview
220.127.116.11. Financial Overview
18.104.22.168. Strategic Overview
22.214.171.124. SWOT Analysis
14.2.4. Pfizer, Inc.
126.96.36.199. Company Description
188.8.131.52. Business Overview
184.108.40.206. Financial Overview
220.127.116.11. Strategic Overview
18.104.22.168. SWOT Analysis
14.2.5. Mylan, Inc., (Viatris)
22.214.171.124. Company Description
126.96.36.199. Business Overview
188.8.131.52. Financial Overview
184.108.40.206. Strategic Overview
220.127.116.11. SWOT Analysis
18.104.22.168. Company Description
22.214.171.124. Business Overview
126.96.36.199. Financial Overview
188.8.131.52. Strategic Overview
184.108.40.206. SWOT Analysis
14.2.7. Johnson & Johnson (Johnson & Johnson Consumer, Inc.)
220.127.116.11. Company Description
18.104.22.168. Business Overview
22.214.171.124. Financial Overview
126.96.36.199. Strategic Overview
188.8.131.52. SWOT Analysis
14.2.8. Sun Pharmaceutical Industries Ltd.
184.108.40.206. Company Description
220.127.116.11. Business Overview
18.104.22.168. Financial Overview
22.214.171.124. Strategic Overview
126.96.36.199. SWOT Analysis
14.2.9. Environmental Tectonics Corporation
188.8.131.52. Company Description
184.108.40.206. Business Overview
220.127.116.11. Financial Overview
18.104.22.168. Strategic Overview
22.214.171.124. SWOT Analysis
14.2.10. Sechrist Industries, Inc.
126.96.36.199. Company Description
188.8.131.52. Business Overview
184.108.40.206. Financial Overview
220.127.116.11. Strategic Overview
18.104.22.168. SWOT Analysis
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111548/2900
You can place an order or ask any questions, please feel free to contact email@example.com | +1 9197 992 333
QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.
For Latest Update Follow Us: